Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma

Oncogene

Volumn 27, Issue 18, 2008, Pages 2613-2625

  Stocklein H ^a   Smardova, J ^b   Macak, J ^b   Katzenberger, T ^a   Holler S ^a   Wessendorf, S ^c   Hutter, G ^d   Dreyling, M ^d   Haralambieva, E ^a   Mader U ^a   Muller Hermelink H K ^a   Rosenwald, A ^a   Ott, G ^a,e   Kalla, J ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c UNIVERSITY OF ULM   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

Del(17p); Diffuse large B cell lymphoma; HIC1; TP53

Indexed keywords

PROTEIN P53;

ADULT; AGED; ALLELE; ARTICLE; B CELL LYMPHOMA; BACTERIAL ARTIFICIAL CHROMOSOME; CHROMOSOME 17P; CHROMOSOME DELETION; CHROMOSOME MAP; FEMALE; GENE MAPPING; HIC1 GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TELOMERE; TUMOR SUPPRESSOR GENE;

BACTERIA (MICROORGANISMS);

EID: 42249115336     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210901     Document Type: Article

References (58)

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511.
2. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V et al. (2005). Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 106: 3183-3190.
3. Britschgi C, Rizzi M, Grob TJ, Tschan MP, Hugli B, Reddy VA et al. (2006). Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene hypermethylated in cancer 1. Oncogene 25: 2030-2039.
4. Chen CM, Behringer RR. (2004). Ovca1 regulates cell proliferation, embryonic development, and tumorigenesis. Genes Dev 18: 320-332.
5. Chen W, Cooper TK, Zahnow CA, Overholtzer M, Zhao Z, Ladanyi M et al. (2004). Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. Cancer Cell 6: 387-398.
6. Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB. (2005). Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 123: 437-448.
7. Chen WY, Zeng X, Carter MG, Morrell CN, Chiu Yen RW, Esteller Met al. (2003). Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet 33: 197-202.
8. Deltour S, Guerardel C, Leprince D. (1999). Recruitment of SMRT/ N-CoR-mSin3A-HDAC-repressing complexes is not a general mechanism for BTB/POZ transcriptional repressors: the case of HIC-1 and gammaFBP-B. Proc Natl Acad Sci USA 96: 14831-14836.
9. Deltour S, Pinte S, Guerardel C, Wasylyk B, Leprince D. (2002). The human candidate tumor suppressor gene HIC1 recruits CtBP through a degenerate GLDLSKK motif. Mol Cell Biol 22: 4890-4901.
10. Dong SM, Kim HS, Rha SH, Sidransky D. (2001). Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res 7: 1982-1986.
11. Duddy PM, Hanby AM, Barnes DM, Camplejohn RS. (2000). Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay. J Mol Diagn 2: 139-144.
12. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P et al. (1995). A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 92: 3963-3967.
13. Goff LK, Neat MJ, Crawley CR, Jones L, Jones E, Lister TA et al. (2000). The use of real-time quantitative polymerase chain reaction and comparative genomic hybridization to identify amplification of the REL gene in follicular lymphoma. Br J Haematol 111: 618-625.
14. Guerardel C, Deltour S, Pinte S, Monte D, Begue A, Godwin AK et al. (2001). Identification in the human candidate tumor suppressor gene HIC-1 of a new major alternative TATA-less promoter positively regulated by p53. J Biol Chem 276: 3078-3089.
15. Haralambieva E, Kleiverda K, Mason DY, Schuuring E, Kluin PM. (2002). Detection of three common translocation breakpoints in non-Hodgkin's lymphomas by fluorescence in situ hybridization on routine paraffin-embedded tissue sections. J Pathol 198: 163-170.
16. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. (1996). Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826.
17. Hida Y, Kubo Y, Murao K, Arase S. (2007). Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch Dermatol Res 299: 103-106.
18. Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A et al. (2007). SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 67: 6612-6618.
19. Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K et al. (1997). Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337: 529-534.
20. Ishioka C, Frebourg T, Yan YX, Vidal M, Friend SH, Schmidt S et al. (1993). Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet 5: 124-129.
21. Issa JP, Zehnbauer BA, Kaufmann SH, Biel MA, Baylin SB. (1997). HIC1 hypermethylation is a late event in hematopoietic neoplasms. Cancer Res 57: 1678-1681.
22. Jaffe E, Harris NL, Stein H, Vardiman JW (eds.) (2001). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon.
23. Kanai Y, Hui AM, Sun L, Ushijima S, Sakamoto M, Tsuda H et al. (1999). DNA hypermethylation at the D17S5 locus and reduced HIC-1 mRNA expression are associated with hepatocarcinogenesis. Hepatology 29: 703-709.
24. Knudson Jr AG. (1971). Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68: 820-823.
25. Koduru PR, Raju K, Vadmal V, Menezes G, Shah S, Susin M et al. (1997). Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. Blood 90: 4078-4091.
26. Konishi H, Sugiyama M, Mizuno K, Saito H, Yatabe Y, Takahashi T et al. (2003). Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at distal 17p13.3 in human lung cancer. Oncogene 22: 1892-1905.
27. Leroy K, Haioun C, Lepage E, Le Metayer N, Berger F, Labouyrie E et al. (2002). p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol 13: 1108-1115.
28. Lichter P, Bentz M, Joos S. (1995). Detection of chromosomal aberrations by means of molecular cytogenetics: painting of chromosomes and chromosomal subregions and comparative genomic hybridization. Methods Enzymol 254: 334-359.
29. Lossos IS. (2005). Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol 23: 6351-6357.
30. Meinhold-Heerlein I, Ninci E, Ikenberg H, Brandstetter T, Ihling C, Schwenk I et al. (2001). Evaluation of methods to detect p53 mutations in ovarian cancer. Oncology 60: 176-188.
31. Melki JR, Vincent PC, Clark SJ. (1999). Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 59: 3730-3740.
32. Nenutil R, Smardova J, Pavlova S, Hanzelkova Z, Muller P, Fabian P et al. (2005). Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 207: 251-259.
33. Phillips NJ, Ziegler MR, Radford DM, Fair KL, Steinbrueck T, Xynos FP et al. (1996). Allelic deletion on chromosome 17p13.3 in early ovarian cancer. Cancer Res 56: 606-611.
34. Pinte S, Stankovic-Valentin N, Deltour S, Rood BR, Guerardel C, Leprince D. (2004). The tumor suppressor gene HIC1 (hypermethylated in cancer 1) is a sequence-specific transcriptional repressor: definition of its consensus binding sequence and analysis of its DNA binding and repressive properties. J Biol Chem 279: 38313-38324.
35. Pinyol M, Hernandez L, Martinez A, Cobo F, Hernandez S, Bea S et al. (2000). INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. Am J Pathol 156: 1987-1996.
36. Prowse AH, Vanderveer L, Milling SW, Pan ZZ, Dunbrack RL, Xu XX et al. (2002). OVCA2 is downregulated and degraded during retinoid-induced apoptosis. Int J Cancer 99: 185-192.
37. Rathi A, Virmani AK, Harada K, Timmons CF, Miyajima K, Hay RJ et al. (2003). Aberrant methylation of the HIC1 promoter is a frequent event in specific pediatric neoplasms. Clin Cancer Res 9: 3674-3678.
38. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. (2005). Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434: 113-118.
39. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al. (2002). The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346: 1937-1947.
40. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD et al. (2003a). Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198: 851-862.
41. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E et al. (2003b). The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3: 185-197.
42. Rudiger T, Ott G, Ott MM, Muller-Deubert SM, Muller-Hermelink HK. (1998). Differential diagnosis between classic Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and paragranuloma by paraffin immunohistochemistry. Am J Surg Pathol 22: 1184-1191.
43. Sankar M, Tanaka K, Kumaravel TS, Arif M, Shintani T, Yagi S et al. (1998). Identification of a commonly deleted region at 17p13.3 in leukemia and lymphoma associated with 17p abnormality. Leukemia 12: 510-516.
44. Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L et al. (2003). The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102: 3871-3879.
45. Saxena A, Clark WC, Robertson JT, Ikejiri B, Oldfield EH, Ali IU. (1992). Evidence for the involvement of a potential second tumor suppressor gene on chromosome 17 distinct from p53 in malignant astrocytomas. Cancer Res 52: 6716-6721.
46. Schlegelberger B, Zwingers T, Harder L, Nowotny H, Siebert R, Vesely M et al. (1999). Clinicopathogenetic significance of chromosomal abnormalities in patients with blastic peripheral B-cell lymphoma. Kiel-Wien-Lymphoma Study Group. Blood 94: 3114-3120.
47. Schultz DC, Vanderveer L, Berman DB, Hamilton TC, Wong AJ, Godwin AK. (1996). Identification of two candidate tumor suppressor genes on chromosome 17p13.3. Cancer Res 56: 1997-2002.
48. Seitz S, Poppe K, Fischer J, Nothnagel A, Estevez-Schwarz L, Haensch W et al. (2001). Detailed deletion mapping in sporadic breast cancer at chromosomal region 17p13 distal to the TP53 gene: association with clinicopathological parameters. J Pathol 194: 318-326.
49. Shaffer LG, Tommerup N. (2005). An International System for Human Cytogenetic Nomenclature. S Karger AG: Memphis, TN, USA.
50. Smardova J, Nemajerova A, Trbusek M, Vagunda V, Kovarik J. (2001). Rare somatic p53 mutation identified in breast cancer: a case report. Tumour Biol 22: 59-66.
51. Stokke T, DeAngelis P, Smedshammer L, Galteland E, Steen HB, Smeland EB et al. (2001). Loss of chromosome 11q21-23.1 and 17p and gain of chromosome 6p are independent prognostic indicators in B-cell non-Hodgkin's lymphoma. Br J Cancer 85: 1900-1913.
52. Stokke T, Galteland E, Holte H, Smedshammer L, Suo Z, Smeland EB et al. (2000). Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell Non-Hodgkin's lymphoma. Int J Cancer 89: 313-324.
53. von Bergh A, Emanuel B, van Zelderen-Bhola S, Smetsers T, van Soest R, Stul M et al. (2000). A DNA probe combination for improved detection of MLL/11q23 breakpoints by double-color interphase-FISH in acute leukemias. Genes Chromosomes Cancer 28: 14-22.
54. Waha A, Koch A, Hartmann W, Mack H, Schramm J, Sorensen N et al. (2004). Analysis of HIC-1 methylation and transcription in human ependymomas. Int J Cancer 110: 542-549.
55. Wales MM, Biel MA, el Deiry W, Nelkin BD, Issa JP, Cavenee WK et al. (1995). p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med 1: 570-577.
56. Waridel F, Estreicher A, Bron L, Flaman JM, Fontolliet C, Monnier P et al. (1997). Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract. Oncogene 14: 163-169.
57. Zettl A, Strobel P, Wagner K, Katzenberger T, Ott G, Rosenwald A et al. (2000). Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol 157: 257-266.
58. Zhang Q, Wang SY, Fleuriel C, Leprince D, Rocheleau JV, Piston DW et al. (2007). Metabolic regulation of SIRT1 transcription via a HIC1:CtBP corepressor complex. Proc Natl Acad Sci USA 104: 829-833.